No protocol for preoperative or postoperative adjuvant therapy was in operation at the time of this study. Some patients with stage IIIa disease were referred for postoperative radiotherapy either because of chest wall or mediastinal lymph node invasion, but this was at the discretion of the operating surgeon.
Complete follow up was available for all patients for 60 months.
STATISTICAL METHODS
All values are represented as means and survival analysis was calculated using the Kaplan-Meier product limits method with 95% confidence interval for survival function. The log rank test was used to calculate the difference between survival curves. The Student's t test was used to test the difference between groups, a p value of <0.05 being considered significant.
Results
In the 123 patients with stage I disease the three and five year survivals were 72.5% (95% CI 64.3% to 80.7%) and 59.4% (95% CI 50.8% to 68%), respectively (fig 1) . No significant difference in survival was noted between patients with T1 (n = 34) and T2 (n = 89) disease, but the five year survival in these groups was 68% and 58%, respectively. Patients with squamous carcinoma had a five year survival of 69.4% compared with 52.6% for those with adenocarcinoma, but this again was not significant (p = 0.1). In this group age, sex, and extent ofresection made no difference.
In fig  2) . The difference in survival between these groups was therefore 21.9% (95% CI 5% to 38.8%). Cell type, age, sex, and extent of resection were again insignificant.
Patients with stage IIIa disease (n = 37) had a five year survival of 16.2% (95% CI 3.5% to 31%). In the 28 patients with N2 disease the three and five year survivals were 21.4% and 14.3%. Although this was poorer than for patients with no N2 nodes (27.3% and 17.2%), the numbers were small and the differences did not reach significance (p = 0.8). Cell type, sex, and extent of resection were insignificant.
In the whole patient population 60% had squamous carcinoma and 30% adeno- 
